Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN

Epidemiological Study to Describe Non-small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Europe. Lung

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00831909

Acronym

EPICLIN

Enrollment

3513

Registered

2009-01-29

Start date

2009-01-31

Completion date

2010-07-31

Last updated

2010-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Keywords

Lung Cancer, NSCLC management, NSCLC use of health care resources

Brief summary

To provide accurate and reliable information regarding NSCLC clinical management across European countries in order to detect unmet medical needs of this disease in terms of: patient and hospital characteristics; diagnostic and treatment approaches: initial and subsequent, follow-up patterns in clinical management; outcomes: symptoms, death, functionality, quality of life; use of resources and burden on patients and health care systems.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed NSCLC diagnosis (e.g. bronchoscope or FNAB), all stages, men and women, attending the responsible department of treating this type of patients for the first time between January 1st, 2009 and March 31st, 2009. * For PRO sub-sample: ability to read and write since they will be asked to participate in the PRO part of the study. Selection will not be based on the disease stage of each patient, in order to avoid a selection bias.

Exclusion criteria

* According to the study design there will not be any

Design outcomes

Primary

Measure	Time frame
To provide accurate, reliable information on NSCLC clinical management across European countries in order to detect unmet medical needs of this disease	1 year follow up

Secondary

Measure	Time frame
To assess the differences in patient characteristics, disease stage (differentiating between non-advanced disease, locally advanced disease, metastatic disease), and in clinical management across European countries.	1 year follow up
To detect differences in clinical outcomes and related factors among countries.	1 year follow up
To identify factors associated with clinical outcomes (patient, disease stage and clinical management related factors): predictive modelling for improved patient outcome.	1 year follow up
To identify factors associated with the different levels of functional status and quality of life.	1 year follow up
To compare the use of health care resources among countries.	1 year follow up

Countries

Belgium, France, Germany, Greece, Italy, Portugal, Spain, Turkey (Türkiye)

Outcome results